249 related articles for article (PubMed ID: 19470922)
1. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; LaPlant B; Bowen DA; Roos M; Secreto CR; Ghosh AK; Kabat BF; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
J Clin Oncol; 2009 Aug; 27(23):3808-14. PubMed ID: 19470922
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; Leis JF; LaPlant B; Bowen DA; Roos M; Laumann K; Ghosh AK; Lesnick C; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
Cancer; 2013 Jan; 119(2):363-70. PubMed ID: 22760587
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies.
Shanafelt TD; Lee YK; Call TG; Nowakowski GS; Dingli D; Zent CS; Kay NE
Leuk Res; 2006 Jun; 30(6):707-12. PubMed ID: 16325256
[TBL] [Abstract][Full Text] [Related]
4. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
[TBL] [Abstract][Full Text] [Related]
5. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
[TBL] [Abstract][Full Text] [Related]
6. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.
Chow HH; Cai Y; Hakim IA; Crowell JA; Shahi F; Brooks CA; Dorr RT; Hara Y; Alberts DS
Clin Cancer Res; 2003 Aug; 9(9):3312-9. PubMed ID: 12960117
[TBL] [Abstract][Full Text] [Related]
8. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E).
Fu H; He J; Mei F; Zhang Q; Hara Y; Ryota S; Lubet RA; Chen R; Chen DR; You M
Cancer Prev Res (Phila); 2009 Jun; 2(6):531-7. PubMed ID: 19470785
[TBL] [Abstract][Full Text] [Related]
9. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Crew KD; Brown P; Greenlee H; Bevers TB; Arun B; Hudis C; McArthur HL; Chang J; Rimawi M; Vornik L; Cornelison TL; Wang A; Hibshoosh H; Ahmed A; Terry MB; Santella RM; Lippman SM; Hershman DL
Cancer Prev Res (Phila); 2012 Sep; 5(9):1144-54. PubMed ID: 22827973
[TBL] [Abstract][Full Text] [Related]
10. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
12. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.
Call TG; Norman AD; Hanson CA; Achenbach SJ; Kay NE; Zent CS; Ding W; Cerhan JR; Rabe KG; Vachon CM; Hallberg EJ; Shanafelt TD; Slager SL
Cancer; 2014 Jul; 120(13):2000-5. PubMed ID: 24711224
[TBL] [Abstract][Full Text] [Related]
13. Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J Mice.
Zhang Q; Fu H; Pan J; He J; Ryota S; Hara Y; Wang Y; Lubet RA; You M
Pharm Res; 2010 Jun; 27(6):1066-71. PubMed ID: 20112129
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.
Gee JR; Saltzstein DR; Kim K; Kolesar J; Huang W; Havighurst TC; Wollmer BW; Stublaski J; Downs T; Mukhtar H; House MG; Parnes HL; Bailey HH
Cancer Prev Res (Phila); 2017 May; 10(5):298-307. PubMed ID: 28325826
[TBL] [Abstract][Full Text] [Related]
15. Modulation of human glutathione s-transferases by polyphenon e intervention.
Chow HH; Hakim IA; Vining DR; Crowell JA; Tome ME; Ranger-Moore J; Cordova CA; Mikhael DM; Briehl MM; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1662-6. PubMed ID: 17684143
[TBL] [Abstract][Full Text] [Related]
16. Natural products and the treatment of leukemia.
Hamblin T
Leuk Res; 2006 Jun; 30(6):649-50. PubMed ID: 16337269
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Joe AK; Schnoll-Sussman F; Bresalier RS; Abrams JA; Hibshoosh H; Cheung K; Friedman RA; Yang CS; Milne GL; Liu DD; Lee JJ; Abdul K; Bigg M; Foreman J; Su T; Wang X; Ahmed A; Neugut AI; Akpa E; Lippman SM; Perloff M; Brown PH; Lightdale CJ
Cancer Prev Res (Phila); 2015 Dec; 8(12):1131-7. PubMed ID: 26471236
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.
Ghosh AK; Kay NE; Secreto CR; Shanafelt TD
Clin Cancer Res; 2009 Feb; 15(4):1250-8. PubMed ID: 19228728
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of intestinal tumorigenesis in Apc(min/+) mice by green tea polyphenols (polyphenon E) and individual catechins.
Hao X; Sun Y; Yang CS; Bose M; Lambert JD; Ju J; Lu G; Lee MJ; Park S; Husain A; Wang S
Nutr Cancer; 2007; 59(1):62-9. PubMed ID: 17927503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
